Xenon Pharmaceuticals Inc. (XENE)
Largest Insider Buys in Sector
XENE Stock Price History Chart
XENE Stock Performance
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise …
Insider Activity of Xenon Pharmaceuticals Inc.
Over the last 12 months, insiders at Xenon Pharmaceuticals Inc. have bought $0 and sold $2.1M worth of Xenon Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Xenon Pharmaceuticals Inc. have bought $235,534 and sold $3.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,400 shares for transaction amount of $40,334 was made by KENNEY CHRISTOPHER JOHN (Chief Medical Officer) on 2022‑01‑21.
List of Insider Buy and Sell Transactions, Xenon Pharmaceuticals Inc.
| 2024-03-08 | Sale | director | 2,092 0.0027% | $45.69 | $95,583 | -11.88% | ||
| 2024-03-07 | Sale | EVP, Strategy & Innovation | 7,137 0.0095% | $46.28 | $330,290 | -11.63% | ||
| 2024-03-07 | Sale | director | 13,000 0.0173% | $46.28 | $601,615 | -11.63% | ||
| 2023-12-14 | Sale | director | 7,598 0.0103% | $41.05 | $311,898 | +1.47% | ||
| 2023-12-13 | Sale | director | 18,978 0.0257% | $39.99 | $758,983 | +4.83% | ||
| 2023-08-24 | Sale | director | 25,000 0.0391% | $38.70 | $967,500 | +5.40% | ||
| 2023-06-01 | Sale | director | 31,713 0.0485% | $38.82 | $1.23M | +2.68% | ||
| 2023-05-31 | Sale | director | 62,526 0.0956% | $38.70 | $2.42M | +2.88% | ||
| 2023-05-30 | Sale | director | 37,006 0.0576% | $39.28 | $1.45M | +3.31% | ||
| 2023-05-24 | Sale | PRESIDENT & CEO | 31,655 0.0482% | $41.41 | $1.31M | -3.86% | ||
| 2023-03-24 | Sale | Chief Medical Officer | 700 0.0011% | $35.01 | $24,507 | +10.93% | ||
| 2023-03-07 | Sale | director | 19,232 0.03% | $36.98 | $711,199 | +6.69% | ||
| 2022-11-25 | Sale | director | 1,937 0.0032% | $34.79 | $67,390 | +8.16% | ||
| 2022-09-02 | Sale | Chief Financial Officer | 15,355 0.0238% | $39.57 | $607,597 | -3.33% | ||
| 2022-08-31 | Sale | EVP, Strategy & Innovation | 8,776 0.0134% | $38.80 | $340,509 | -2.80% | ||
| 2022-08-12 | Sale | 32,058 0.0495% | $38.29 | $1.23M | -0.50% | |||
| 2022-08-12 | Sale | EVP, Drug Discovery | 21,875 0.0341% | $38.68 | $846,125 | -0.50% | ||
| 2022-03-08 | Sale | director | 5,000 0.0092% | $30.80 | $154,000 | +17.14% | ||
| 2022-03-07 | Sale | director | 31,086 0.0572% | $30.50 | $948,260 | +18.01% | ||
| 2022-03-07 | Sale | EVP, Drug Discovery | 32,853 0.0606% | $30.54 | $1M | +18.01% |
Insider Historical Profitability
| PATOU GARY | director | 4902 0.0065% | $44.91 | 2 | 3 | +22.07% |
| GANNON STEVEN | director | 2000 0.0026% | $44.91 | 1 | 1 | +31.48% |
| BVF PARTNERS L P/IL | 10 percent owner | 1674468 2.2101% | $44.91 | 10 | 0 | <0.0001% |
| Hayden Michael R | director | 161187 0.2127% | $44.91 | 1 | 0 | +44.5% |
| AZAB MOHAMMAD | director | 57561 0.076% | $44.91 | 5 | 1 | +72.32% |
Institutional Investor Ownership
| Fidelity Investments | $284.21M | 8.75 | 6.6M | +16.72% | +$40.72M | 0.02 | |
| Avoro Capital Advisors Llc | $243.95M | 7.51 | 5.67M | 0% | +$0 | 2.92 | |
| Driehaus Capital Management LLC | $186.05M | 5.73 | 4.32M | -0.54% | -$1.01M | 1.85 | |
| Wellington Management Company | $168.84M | 5.2 | 3.92M | -5.78% | -$10.36M | 0.03 | |
| Capital World Investors | $115.44M | 3.55 | 2.68M | 0% | +$0 | 0.02 |